drugset / Trial / NCT06045091
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.
Timeline
- Start
- 2023-07-04
- Primary completion
- 2025-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human BCMA targeted CAR-NK cells injection | Cell therapy | 1.5e+08 cells | Other |
| Subject | Human BCMA targeted CAR-NK cells injection | Cell therapy | 3e+08 cells | Other |
| Subject | Human BCMA targeted CAR-NK cells injection | Cell therapy | 6e+08 cells | Other |